EA202090928A1 - Имипридоны для глиом - Google Patents

Имипридоны для глиом

Info

Publication number
EA202090928A1
EA202090928A1 EA202090928A EA202090928A EA202090928A1 EA 202090928 A1 EA202090928 A1 EA 202090928A1 EA 202090928 A EA202090928 A EA 202090928A EA 202090928 A EA202090928 A EA 202090928A EA 202090928 A1 EA202090928 A1 EA 202090928A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
imipridone
subject
conditions
methods
Prior art date
Application number
EA202090928A
Other languages
English (en)
Inventor
Джошуа Э. Аллен
Мартин Стогнев
Варун Виджай Прабху
Original Assignee
Онкосьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Онкосьютикс, Инк. filed Critical Онкосьютикс, Инк.
Publication of EA202090928A1 publication Critical patent/EA202090928A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Имипридоны селективно модулируют рецепторы, связанные с G-белком (GPCR) класса A, такие как подсемейство D2-подобных рецепторов допамина, и подходят для лечения состояний и расстройств, нуждающихся в такой модуляции, таких как рак, в частности рак, поражающий структуру срединной линии мозга, рак, имеющий мутацию гистона H3, или оба варианта. Кроме того, предложены способы идентификации, является ли субъект, имеющий такие состояния, вероятно чувствительным к режиму лечения, такому как введение имипридона. Кроме того, предложены способы оценки эффективности режима лечения, такие как введение имипридона, контроль или обеспечение прогноза для субъекта с таким состоянием.
EA202090928A 2017-11-03 2018-11-05 Имипридоны для глиом EA202090928A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762581478P 2017-11-03 2017-11-03
US15/947,840 US10172862B2 (en) 2017-01-30 2018-04-08 Imipridones for gliomas
PCT/US2018/059209 WO2019090222A1 (en) 2017-11-03 2018-11-05 Imipridones for gliomas

Publications (1)

Publication Number Publication Date
EA202090928A1 true EA202090928A1 (ru) 2020-08-14

Family

ID=63038820

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090928A EA202090928A1 (ru) 2017-11-03 2018-11-05 Имипридоны для глиом

Country Status (14)

Country Link
US (4) US10172862B2 (ru)
EP (1) EP3703681A4 (ru)
JP (2) JP7319989B2 (ru)
KR (1) KR20200117979A (ru)
CN (2) CN116173036A (ru)
AU (1) AU2018360752A1 (ru)
BR (1) BR112020008791A2 (ru)
CA (1) CA3080815A1 (ru)
EA (1) EA202090928A1 (ru)
IL (1) IL274194A (ru)
MA (1) MA50533A (ru)
MX (1) MX2020004375A (ru)
SG (1) SG11202003952YA (ru)
WO (1) WO2019090222A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201806401YA (en) 2016-01-29 2018-08-30 Oncoceutics Inc G protein-coupled receptor (gpcr) modulation by imipridones
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
WO2020172485A1 (en) * 2019-02-22 2020-08-27 Board Of Regents, The University Of Texas System Methods of using imipridones
JP2023536524A (ja) 2020-08-06 2023-08-25 エトヴェシュ ロラーンド トゥドマニュジェテム 新規イミプリドン誘導体の合成とその抗癌活性の評価
CN113248465B (zh) * 2021-06-16 2021-10-29 中国农业科学院北京畜牧兽医研究所 一种鹰嘴豆芽素a的合成方法
CN114632088B (zh) * 2022-05-16 2022-08-16 北京市神经外科研究所 阿糖胞苷化合物在制备治疗脊髓胶质瘤的药物中的用途
WO2024030645A1 (en) * 2022-08-05 2024-02-08 Chimerix, Inc. Pharmaceutical compositions and uses thereof for the treatment of glioma
CN117731654B (zh) * 2024-02-18 2024-05-07 首都医科大学附属北京天坛医院 Jjh201601在初发性脑胶质瘤和复发性脑胶质瘤治疗中的新用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1638178A (en) * 1924-11-04 1927-08-09 Union Switch & Signal Co Railway-traffic-controlling apparatus
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
WO2004082570A2 (en) 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2)
AU2004258147B2 (en) 2003-07-08 2009-04-30 State Of Queensland Acting Through Queensland Health Genetic marker of response to atypical antipsychotics and antidepressants and methods for use thereof
US8088895B2 (en) 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
US8463365B2 (en) * 2007-09-19 2013-06-11 Oncofluor, Inc. Method for imaging and treating organs and tissues
WO2011160206A1 (en) * 2010-06-23 2011-12-29 Morin Ryan D Biomarkers for non-hodgkin lymphomas and uses thereof
US20130331381A1 (en) 2011-02-28 2013-12-12 Mcmaster University Treatment of Cancer WIth Dopamine Receptor Antagonists
JP6132833B2 (ja) 2011-04-29 2017-05-24 ザ ペン ステイト リサーチ ファンデーション 抗癌療法としての正常細胞および腫瘍細胞の小分子ｔｒａｉｌ遺伝子誘導
US9688679B2 (en) * 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
WO2015073072A1 (en) 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
WO2014160130A1 (en) * 2013-03-13 2014-10-02 Oncoceutics, Inc. Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
DK3546461T3 (da) * 2013-11-15 2021-09-13 Oncoceutics Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of using the same in combination therapy
JP6756435B2 (ja) 2014-03-31 2020-09-16 ザ スクリプス リサーチ インスティテュート Ｔｒａｉｌ誘導のためのファーマコフォア
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
SG11201806401YA (en) * 2016-01-29 2018-08-30 Oncoceutics Inc G protein-coupled receptor (gpcr) modulation by imipridones
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas

Also Published As

Publication number Publication date
IL274194A (en) 2020-06-30
CN111818919A (zh) 2020-10-23
EP3703681A4 (en) 2021-08-11
US10369154B2 (en) 2019-08-06
US20190183895A1 (en) 2019-06-20
US20200022982A1 (en) 2020-01-23
SG11202003952YA (en) 2020-05-28
JP2023139152A (ja) 2023-10-03
US10172862B2 (en) 2019-01-08
AU2018360752A1 (en) 2020-05-21
MA50533A (fr) 2020-09-09
JP7319989B2 (ja) 2023-08-02
CN116173036A (zh) 2023-05-30
US20210236499A1 (en) 2021-08-05
MX2020004375A (es) 2020-11-11
JP2021502417A (ja) 2021-01-28
BR112020008791A2 (pt) 2020-10-20
KR20200117979A (ko) 2020-10-14
US20180221375A1 (en) 2018-08-09
WO2019090222A1 (en) 2019-05-09
US10946022B2 (en) 2021-03-16
EP3703681A1 (en) 2020-09-09
CA3080815A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
EA202090928A1 (ru) Имипридоны для глиом
BR112018015590A2 (pt) modulação de receptor acoplado à proteína g (gpcr) por imipridonas
BR112017024555A2 (pt) moduladores de ccr2
EA201891799A1 (ru) Замещенные 1,2,3-триазолы в качестве nr2b-селективных модуляторов nmda
CL2016002683A1 (es) Proteínas agonistas de los receptores de trail de cadena simple
EA201501122A8 (ru) Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4)
BR112014029588A2 (pt) sistema e métodos para detectar distúrbios de saúde
BR112017023646A2 (pt) proteínas agonistas de receptor de cd40 de cadeia simples
EA202091342A3 (ru) Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения
EA201991345A1 (ru) Новые соединения в качестве пептидных тройных агонистов рецепторов glp1/глюкагона/gip
BR112015023534A2 (pt) sistema e método para monitorar e diagnosticar condição de paciente com base em dados de monitoramento de sensor sem fio
BR112015026122A2 (pt) métodos para usar interleucina-10 para tratar doenças e desordens
BR112016005634A2 (pt) categorizar solicitantes de seguros de vida para determinar produtos de seguros de vida adequados
EA201591839A1 (ru) Терапевтические пептиды
EA201790896A1 (ru) Пролекарства фенольных агонистов trpv1
FR3033061B1 (fr) Systeme et procede de copie a l'ecriture sur un ssd
BR112014002363A2 (pt) agonistas do domínio de homologia src 2 contendo proteína tirosina fosfatase - 1 e métodos de tratamento utilizando os mesmos
EA201390070A1 (ru) Лечение расстройств, вызванных l-dopa, дофаминовым агонистом и/или усилителем дофамина
CY1122474T1 (el) Μεθοδος διαγνωσης νευραλγιας του τριδυμου
EA201991985A1 (ru) Конъюгаты антитело-лекарственное средство (калс) на основе ингибиторов гдац и применение в терапии
BR112017004883A2 (pt) ensaio de diagnóstico baseado em fragmento de rgma
UY33496A (es) Derivados heterociclicos fusionados como moduladores s1p
MX2015014825A (es) Ensayos para la identificacion de compuestos que modulan el sabor amargo.
PH12017502099A1 (en) Methods for diagnosing and assessing treatment for cushing's syndrome
EA201591123A1 (ru) Комбинации агониста glp1r и метформина, а также способ их применения при лечении диабета 2 типа и прочих расстройств